CLINICAL EVENTS CALENDAR
Non-Accredited Education
CLINICAL EXPERIENCE WITH A NEW HYBRID CORONARY WIRE
On Demand Web ArchiveNon-Accredited
Target Audience: Physicians, nurses, and technologists.
This activity is supported by an educational grant from Terumo Medical Corporation.
Issue
- Issue Number:3
The incidence of puncture-related femoral artery pseudoaneurysms (PSA) is relatively low but not insignificant. Unlike PSAs of a surgical or post-traumatic nature, catheterization-induced pseudoaneurysms (Figure 1) have a largely benign natural history. Clinical manifestations include pain — at times severe — and consequent ambulatory limitations. A palpable pulsatile mass is often present. The symptoms tend to be most prominent during the first few days after the procedure. For reasons that are not altogether clear (to me, at least), many if not the majority of surgeons have (over the yea
- Issue Number:3
Introduction
Spontaneous coronary artery dissection (SCD) is an extremely rare condition. It is usually documented during peripartum period in young pregnant women having a history of oral contraceptive use.1 It may also be observed in elderly patients with atherosclerotic disorder.2,3 Spontaneous rupture of vulnerable plaque plays a pivotal role in the pathogenesis of SCD that occurs in these patients. Therapeutic approaches include pharmaceutical, percutaneous coronary interventions or surgery (CABG), although optimal treatment strategy has not been well defined - Issue Number:3
Introduction
Advantages of various direct thrombin inhibitors, a modified dosing schedule for bivalrudin, and experience with monitoring parameters are described. These advantages may form the basis for consideration when alternative anticoagulation to heparin is desired during peripheral vascular procedures.Case Report
An 82-year-old, 65 kg, white male underwent evaluation for progressive fatigue and shortness of breath. He had undergone a Hancock porcine mitral valve replacement in conjunction with a one-vessel coronary artery bypass 12 years previously. He also had a - Issue Number:3
Background
The delivery of adequate hemodialysis requires dependable access to the vascular system of end stage renal disease patients. Despite the recommendation that arteriovenous fistulae (AVF) be used preferentially over arteriovenous grafts (AVG) and central venous catheters (CVC), hemodialysis via arteriovenous fistulae remains the exception rather than the rule.1 Currently, in the United States, up to 60% of incident patients and nearly 30% of prevalent patients are using a central venous catheters for hemodialysis.2,3 Recurrent vascular access failure is a - Issue Number:3
Introduction
It has been suggested that treatment strategies for acute and chronic critical limb ischemia (CLI) can be tailored, analogous to treating chronic, and especially, acute coronary syndromes (ACS).1,2 Mechanical thrombectomy devices, distal protection devices, excimer laser and drug-eluting stents are just a few examples of device technologies first applied in coronary artery disease and ACS that are now increasingly being utilized in the treatment of CLI. Substantial clinical evidence showing improved outcomes exists, supporting the use of novel antiplatelet and a - Issue Number:3
Introduction
The optimal anticoagulant during the treatment of chronic limb ischemia (CLI) is largely unknown. For the past several years, unfractionated heparin (UFH) has been the main anticoagulant utilized by most endovascular specialists in treating CLI. Multiple trials in the coronary literature have shown that UFH is less effective or safe than the direct thrombin inhibitor bivalirudin1–8 or the low-molecular weight heparin enoxaparin.9 In this study, we compare the in-hospital complications of various intraprocedural anticoagulants utilized in the treatme - Issue Number:3
I believe the authors are on the right track by exploring more optimal anticoagulation and antiplatelet strategies in treating patients with peripheral arterial disease (PAD), and especially critical limb ischemia (CLI). The limitations and bleeding complications with unfractionated heparin (UFH) have been well documented during percutaneous coronary intervention (PCI), and likewise over the last several years during percutaneous peripheral intervention (PPI).1,2 The PAD patients, and especially the CLI patients, are at significantly higher risks for all hemorrhagic and thrombotic c
- Issue Number:3
Introduction
Surgical bypass is considered the gold standard for the treatment of patients with chronic severe lower extremity ischemia.1,2 However, the 5-year limb salvage rates reported as high as 80% in single center/surgeon series have not been reproduced in multicenter studies or national registries.1,3,4 Often, these are extensive surgeries being performed in a mostly elderly patient population with multiple comorbidities. This has an impact on functional outcome. Only 45% of patients under going infrainguinal bypass reported feeling “back to normal” at
Digital Supplements Using Advanced Technology to |
 Superior Mesenteric Artery Revascularization and |
Vascular Disease News Wire
- Thursday, December 11, 2008 - 16:23
- Monday, November 24, 2008 - 11:56
- Monday, October 6, 2008 - 10:02
Anytown, California
CME Showcase
"Diabetic Peripheral Neuropathy"
Upcoming Accredited Webcast Release Date: December 22, 2008 Expiration Date: December 22, 2009 This activity is supported by an educational grant from PamLabs. To register for this Webcast, visit www.naccme.com/program/n-558/ |
 LUMEN 2009 - THE SYMPOSIUM ON OPTIMAL TREATMENTS FOR ACUTE MI Live Symposium Date: February 26-28 Location: Loews Miami Beach Hotel Miami Beach, Florida 33139 Phone: (305) 604-1601 Toll Free: 1-877-563-9762 This activity is sponsored by the North American Center for Continuing Medical Education. |
 CARDIAC PET: Optimizing CAD Patient Management with Diagnostic Confidence A Complimentary CME Accredited Lunch Symposium Date: Friday, September 12, 2008 12:00 pm - 1:15 pm Location: Hynes Convention Center 900 Boylston Street, Room 304 Boston, MA 02115 This activity is supported by an educational grant from Bracco Diagnostics Inc. |
REVIEW OUR OTHER
CARDIOLOGY BRANDS
Check out our other resources for healthcare professionals of all specialties.
